Impact of short-term esomeprazole treatment on performance of daily activities and antacid use in patients with nonerosive symptomatic gastro-oesophageal reflux disease (gord) and frequent heartburn
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Poster
- By: KATZ, Philip (Einstein Medical Center, Division of Gastroenterology, Philadelphia, United States of America)
- Co-author(s): Le Moigne, Anne (Pfizer Consumer Healthcare, Madison, United States of America)
Park, Kelly (Pfizer Consumer Healthcare, Madison, United States of America)
Pollack, Charles (Pfizer Consumer Healthcare, Madison, United States of America)
Background: Symptomatic GORD can impair performance of daily activities, and self-treatment of reflux symptoms (e.g., heartburn [HB] and acid regurgitation) with antacids is common. We evaluated patient-reported outcomes and antacid use in 2 studies of short-term esomeprazole (ESO) in patients likely to seek self-treatment in a pharmacy setting.
Se.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.